These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 31136052)

  • 21. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years.
    Hadziyannis SJ; Tassopoulos NC; Heathcote EJ; Chang TT; Kitis G; Rizzetto M; Marcellin P; Lim SG; Goodman Z; Ma J; Brosgart CL; Borroto-Esoda K; Arterburn S; Chuck SL;
    Gastroenterology; 2006 Dec; 131(6):1743-51. PubMed ID: 17087951
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized, double-blind, double-dummy, controlled, multicenter study of Qingzhong (tenofovir disoproxil fumarate) versus Viread for the treatment of chronic hepatitis B: First-stage results at week 48.
    Liang RY; Xu JH; Si CW; Wang S; Shang J; Yu ZJ; Mao Q; Xie Q; Zhao W; Li J; Gao ZL; Wu SM; Tang H; Cheng J; Chen XY; Zhang WH; Wang H; Xu ZN; Wang L; Dai J; Yu YY
    Medicine (Baltimore); 2019 Aug; 98(33):e16778. PubMed ID: 31415381
    [TBL] [Abstract][Full Text] [Related]  

  • 23. No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg- patients with chronic hepatitis B after 8 years of treatment.
    Liu Y; Corsa AC; Buti M; Cathcart AL; Flaherty JF; Miller MD; Kitrinos KM; Marcellin P; Gane EJ
    J Viral Hepat; 2017 Jan; 24(1):68-74. PubMed ID: 27658343
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year Prospective Field Practice Study in Germany.
    Petersen J; Heyne R; Mauss S; Schlaak J; Schiffelholz W; Eisenbach C; Hartmann H; Wiese M; Boeker K; Loehr HF; John C; Leuschner M; Trautwein C; Felten G; Trein A; Krause W; Ruppert S; Warger T; Hueppe D
    Dig Dis Sci; 2016 Oct; 61(10):3061-3071. PubMed ID: 26576555
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Compare with safety and efficacy of entecavir and adefovir dipivoxil combination therapy and tenofovir disoproxil fumarate monotherapy for chronic hepatitis B patient with adefovir-resistant.
    Lai MC; Lian JS; Zhang WJ; Xu J; Zhou L; Zheng SS
    Math Biosci Eng; 2019 Oct; 17(1):627-635. PubMed ID: 31731368
    [No Abstract]   [Full Text] [Related]  

  • 26. Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir.
    Hadziyannis SJ; Sevastianos V; Rapti I; Vassilopoulos D; Hadziyannis E
    Gastroenterology; 2012 Sep; 143(3):629-636.e1. PubMed ID: 22659218
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.
    Marcellin P; Gane E; Buti M; Afdhal N; Sievert W; Jacobson IM; Washington MK; Germanidis G; Flaherty JF; Aguilar Schall R; Bornstein JD; Kitrinos KM; Subramanian GM; McHutchison JG; Heathcote EJ
    Lancet; 2013 Feb; 381(9865):468-75. PubMed ID: 23234725
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Peg-interferon plus nucleotide analogue treatment versus no treatment in patients with chronic hepatitis B with a low viral load: a randomised controlled, open-label trial.
    de Niet A; Jansen L; Stelma F; Willemse SB; Kuiken SD; Weijer S; van Nieuwkerk CMJ; Zaaijer HL; Molenkamp R; Takkenberg RB; Koot M; Verheij J; Beuers U; Reesink HW
    Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):576-584. PubMed ID: 28522204
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B.
    Patterson SJ; George J; Strasser SI; Lee AU; Sievert W; Nicoll AJ; Desmond PV; Roberts SK; Locarnini S; Bowden S; Angus PW
    Gut; 2011 Feb; 60(2):247-54. PubMed ID: 21036792
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.
    Hadziyannis SJ; Tassopoulos NC; Heathcote EJ; Chang TT; Kitis G; Rizzetto M; Marcellin P; Lim SG; Goodman Z; Ma J; Arterburn S; Xiong S; Currie G; Brosgart CL;
    N Engl J Med; 2005 Jun; 352(26):2673-81. PubMed ID: 15987916
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Similar evolution of hepatitis B virus quasispecies in patients with incomplete adefovir response receiving tenofovir/emtricitabine combination or tenofovir monotherapy.
    Lavocat F; Dény P; Pichoud C; Al Hawajri N; Kitrinos K; Borroto-Esoda K; Zoulim F
    J Hepatol; 2013 Oct; 59(4):684-95. PubMed ID: 23742912
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Besifovir Dipivoxil Maleate 144-Week Treatment of Chronic Hepatitis B: An Open-Label Extensional Study of a Phase 3 Trial.
    Yim HJ; Kim W; Ahn SH; Yang JM; Jang JY; Kweon YO; Cho YK; Kim YJ; Hong GY; Kim DJ; Jung YK; Um SH; Sohn JH; Lee JW; Park SJ; Lee BS; Kim JH; Kim HS; Yoon SK; Kim MY; Lee KS; Lim YS; Lee WS; Han KH
    Am J Gastroenterol; 2020 Aug; 115(8):1217-1225. PubMed ID: 32355123
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-Term Treatment With Tenofovir Alafenamide for Chronic Hepatitis B Results in High Rates of Viral Suppression and Favorable Renal and Bone Safety.
    Chan HLY; Buti M; Lim YS; Agarwal K; Marcellin P; Brunetto M; Chuang WL; Janssen HLA; Fung S; Izumi N; Abdurakhmanov D; Jabłkowski M; Celen MK; Ma X; Caruntu F; Flaherty JF; Abramov F; Wang H; Camus G; Osinusi A; Pan CQ; Shalimar ; Seto WK; Gane E;
    Am J Gastroenterol; 2024 Mar; 119(3):486-496. PubMed ID: 37561058
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of switching from adefovir to tenofovir in chronic hepatitis B patients who exhibit suboptimal responses to adefovir-based combination rescue therapy due to resistance to nucleoside analogues (SATIS study).
    Lee HW; Park JY; Kim BK; Kim MY; Lee JI; Kim YS; Yoon KT; Han KH; Ahn SH
    Clin Mol Hepatol; 2016 Dec; 22(4):443-449. PubMed ID: 27880997
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B.
    Piccolo P; Lenci I; Demelia L; Bandiera F; Piras MR; Antonucci G; Nosotti L; Mari T; De Santis A; Ponti ML; Sorbello O; Iacomi F; Angelico M
    Antivir Ther; 2009; 14(8):1165-74. PubMed ID: 20032546
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of a 48-week pegylated interferon therapy in hepatitis B e antigen positive HIV-co-infected patients on cART including tenofovir: EMVIPEG study.
    Miailhes P; Maynard-Muet M; Lebossé F; Carrat F; Bouix C; Lascoux-Combe C; Sogni P; Rey D; Barthe Y; Pol S; Cacoub P; Zoulim F; Piroth L
    J Hepatol; 2014 Oct; 61(4):761-9. PubMed ID: 24882048
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tenofovir has inferior efficacy in adefovir-experienced chronic hepatitis B patients compared to nucleos(t)ide-naïve patients.
    Chung GE; Cho EJ; Lee JH; Yoo JJ; Lee M; Cho Y; Lee DH; Kim HY; Yu SJ; Kim YJ; Yoon JH; Zoulim F
    Clin Mol Hepatol; 2017 Mar; 23(1):66-73. PubMed ID: 28190329
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of long-term tenofovir-based rescue therapy in patients with chronic hepatitis B refractory to nucleoside/nucleotide analogs.
    Suzuki F; Suzuki Y; Hosaka T; Sezaki H; Akuta N; Fujiyama S; Kawamura Y; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Mineta R; Suzuki Y; Kumada H
    J Gastroenterol; 2017 May; 52(5):641-651. PubMed ID: 27699721
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of tenofovir disoproxil fumarate in Asian-Americans with chronic hepatitis B in community settings.
    Pan CQ; Trinh H; Yao A; Bae H; Lou L; Chan S;
    PLoS One; 2014; 9(3):e89789. PubMed ID: 24594870
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical effect of entecavir versus tenofovir in treatment of HBeAg-positive chronic hepatitis B patients with a high viral load: a comparative analysis].
    Shi H; Li XY; Zhu JY; Lin CS; Zhang Y
    Zhonghua Gan Zang Bing Za Zhi; 2017 Oct; 25(10):721-725. PubMed ID: 29108198
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.